Vericel Corp Ord (VCEL) Stock Analysis

Vericel Corp Ord (VCEL) is a publicly traded company in the HEALTHCARE sector. It trades at $34.45, carries a market capitalization of $1.70B, a price-to-earnings ratio of 77.51. This page summarizes the public market data, fundamentals, and frequently asked questions for VCEL, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $34.45
• Market Cap: $1.70B
• P/E Ratio: 77.51
• EPS: $0.43
• 52-Week High: $45.97
• 52-Week Low: $28.95

Market Sentiment

Vericel Corp Ord currently has a Neutral sentiment score of 0.02.

About Vericel Corp Ord

Vericel Corporation (VCEL) is a leading commercial-stage biopharmaceutical company focused on innovative cell therapies for the sports medicine and severe burn care sectors in the United States. Headquartered in Cambridge, Massachusetts, Vericel is dedicated to advancing the treatment options for patients through its proprietary products, including MACI® and Epicel®. With a robust commitment to research and development, the company aims to enhance patient outcomes and address unmet medical ne...

GNG Research Analysis

GNG Research scores Vericel Corp Ord (VCEL) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for VCEL.

Frequently Asked Questions

Does VCEL pay dividends?

Vericel Corp Ord (VCEL) does not currently pay a regular dividend.

What is VCEL's P/E ratio?

Vericel Corp Ord has a price-to-earnings (P/E) ratio of 77.51.

What is VCEL's market cap?

Vericel Corp Ord (VCEL) has a market capitalization of $1.70B with a current stock price of $34.45.